Generics
Voluntarily Recall in US of Certain Blister Packs Issued by Sandoz, Novartis
12 July 2018 - - Holzkirchen, Germany-based biosimilar medicines specialist Sandoz, a Novartis division, and East Hanover, New Jersey-based healthcare solutions provider Novartis Pharmaceuticals Corp. have issued a voluntary recall and corrective action notice for certain lots of product distributed in the US in pre-packaged blister card packages after learning that these blister packs do not meet federal standards for child-resistant packaging, posing a risk of harm if the tablets are swallowed by children, the companies said.
Not all medications are involved and only specific national drug numbers and blister pack lots distributed by Sandoz and Novartis in the US are affected.
Patients should continue taking the medicine as directed by their physician, secure the affected blister packs so that they are out of the sight and reach of children, and contact Novartis at 1-888-NOW NOVA or 1-888-669-6682 for full information on the list of affected products and instructions. Products in bottles are NOT impacted by this recall.
Sandoz focuses on generic pharmaceuticals and biosimilars. A division of the Novartis Group, its purpose is to discover new ways to improve and extend people's lives and to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. The company's portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of 10.1 bn. In 2016, its products reached well over 500 million patients.
Novartis Pharmaceuticals is an affiliate of Novartis which provides innovative healthcare solutions that address the evolving needs of patients and societies.
Login
Username:

Password: